Evidence map›Paper›PMID 28361843›Full record

ArticleSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Mahmoud M Mosli, Moaiad Elyas

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022
    Pooled it
  6. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
    Trial
  7. Review
  8. Endoscopic bariatrics: Current status and emerging technologies.World journal of gastrointestinal endoscopy · 2025
    Review
  9. Review
  10. Article
  11. The Evolving Role of Weight Loss Pharmacotherapy.Gastroenterology & hepatology · 2025
    Article
  12. Weight Loss Pharmacotherapy: Current and Future Therapies.Gastrointestinal endoscopy clinics of North America · 2024
    Review
  13. Endobariatric systems: Strategic integration of endoscopic therapies in the management of obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  14. Article
  15. Article
  16. Metabolic and Bariatric Endoscopy: A Mini-Review.Life (Basel, Switzerland) · 2023
    Review
  17. Review
  18. The efficacy of liraglutide combined with intragastric balloon on weight loss.Revista da Associacao Medica Brasileira (1992) · 2023
    Article
  19. Endobariatrics: a Still Underutilized Weight Loss Tool.Current treatment options in gastroenterology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Mahmoud M MosliDepartment of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Moaiad ElyasDepartment of Gastroenterology and Hepatology, Saad Specialist Hospital, Al-Khobar, Kingdom of Saudi Arabia.
Creative Commons · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimIntragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction. PATIENTS AND

methodsA retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared.

resultsA total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78-10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79-188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal.

conclusionsAdding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal.

Indexed as

AdultBariatric SurgeryBody Mass IndexCombined Modality TherapyFemaleGastric BalloonHumansLiraglutideMaleObesity, MorbidRetrospective StudiesTreatment OutcomeLiraglutide

Identifiers

PMID28361843
PMCPMC5385714
OpenAlexW2607144935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.